Shareholder Campaign: Baxter International
Baxter International develops, manufactures, and markets products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions.
2011 Resolution: Transparency in Animal Use
In the fall of 2010, PETA filed a resolution requesting that Baxter issue an annual report to shareholders disclosing the number and species of animals used in-house and at contract laboratories, the number and species of animals used for explicitly required testing and basic research and development, and Baxter’s plans to reduce and phase out animal testing.
The resolution was largely the result of a whistleblower’s report to PETA stating that pigs and dogs at a Baxter laboratory were “screaming as though in terrible pain.” Baxter responded that they had conducted an internal investigation into the matter and found no basis for concerns about animal welfare. However, when PETA pressed Baxter for more information about its investigation, the company did not respond.
Negotiations with Baxter prior to the annual meeting resulted in withdrawal of the resolution when the company agreed to meet with PETA annually and address ongoing issues regarding Baxter’s animal use.